Structure Therapeutics Inc. ADR (GPCR)
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 26.70 +0.07%
GPCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.90B
- EPS (TTM)
- -$2.94
- Dividend yield
- None
- 52-week range
- 25.59 – 94.90
- Day range
- 26.38 – 28.05
- Volume / Avg
- 1.05M / 956.06K
- Beta
- —
- Shares outstanding
- 71.31M
- Next earnings
- Nov 5, 2026
52-week range
GPCR stock today
Shares of Structure Therapeutics (GPCR) finished lower on Oct 7 at $26.68, a drop of 2.88% or $0.79 per share, versus the S&P 500's 0.22% decline. At this level, GPCR sits near the bottom of its 52-week range of $25.59 to $94.90: 71.9% below the high, set on Dec 8, 2025 and 4.3% above the low. GPCR is down 61.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 6.1%.
Structure Therapeutics has posted a net loss over the last twelve months (EPS of -$2.94), so its P/E ratio is not meaningful. Structure Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Structure Therapeutics
Company profileStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Raymond C. Stevens Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 281
- IPO year
- 2023
- Website
- structuretx.com
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$105.78+296.48%
- Strong buy 4
- Buy 11
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.51
Structure Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZYMEZymeworks Inc. | 26.53 | +3.43% | $1.90B | vs GPCR |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs GPCR |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs GPCR |
| MLYSMineralys Therapeutics Inc. | 22.09 | +0.64% | $1.95B | vs GPCR |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs GPCR |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs GPCR |
| LKFTLakefront Biotherapeutics ADR | 30.00 | +2.32% | $1.96B | vs GPCR |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs GPCR |
Indexes, lists and sector
Structure Therapeutics stock FAQ
What is Structure Therapeutics's stock price today?
GPCR last traded at $26.68 as of Oct 7, 4:00 PM EDT, down 2.88% on the day. Prices are delayed at least 15 minutes.
When is Structure Therapeutics's next earnings date?
Structure Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.51.
Who is Structure Therapeutics's CEO?
Dr. Raymond C. Stevens Ph.D. is the chief executive officer of Structure Therapeutics Inc. ADR, which has about 281 employees.
What is the GPCR 52-week high?
The 52-week high for GPCR is $94.90 and the 52-week low is $25.59. The stock is currently 71.9% below its high.